Article Summary
李娜孙朝阳周波郭恩松卢豪陈刚翁丹卉Δ.Cdk1 在浆液性卵巢癌中的表达及其与化疗耐药及预后的相关性*[J].现代生物医学进展英文版,2014,14(8):1467-1470.
Cdk1 在浆液性卵巢癌中的表达及其与化疗耐药及预后的相关性*
Expression of Cdk1 Protein in Serous Ovarian Cancer Correlates toChemo-Resistance and Prognosis of Patients*
  
DOI:
中文关键词: Cdk1  免疫组化  卵巢癌  化疗耐药
英文关键词: Cdk1  IHC  Serous ovarian cancer  Chemo-resistance
基金项目:国家自然科学基金青年基金项目(81000979/H1609);国家自然科学基金项目(81272859);
Author NameAffiliation
LI Na, SUN Chao-yang, ZHOU Bo,GUO En-song, LU Hao, CHEN Gang,WENG Dan-hui 华中科技大学同济医学院附属同济医院妇瘤科湖北武汉430030 
Hits: 937
Download times: 1038
中文摘要:
      摘要目的:卵巢癌是女性生殖致死率最高的恶性肿瘤。Cdk1 作为细胞周期依赖性激酶中的核心分子,对肿瘤细胞的发生发展具 有重要作用。本文旨在探讨Cdk1 蛋白在上皮性浆液性卵巢癌中的表达情况,并分析其表达水平与患者临床病理特征、化疗反应 及预后之间的关系。方法:采用免疫组化法检测68 例浆液性卵巢癌中Cdk1 蛋白的表达情况,并结合临床资料分析Cdk1蛋白的 表达水平在浆液性卵巢癌患者中的意义。结果:Cdk1 在浆液性卵巢癌患者中具有不同程度的阳性表达,其表达水平和患者的年 龄、病理分化程度、淋巴结转移情况及临床分期无明显相关性(P>0.05),但是其高表达与化疗耐药明显相关(P = 0.040)。化疗耐 药的卵巢癌患者中Cdk1 的蛋白表达明显高于化疗敏感组,并且生存分析发现,高表达Cdk1 的患者预后较差。结论:本研究证明 Cdk1 在浆液性卵巢癌中有较高表达,并且Cdk1 的表达与卵巢癌化疗后复发有关,高的Cdk1表达预示着较差的预后。Cdk1 可能 是晚期浆液性卵巢癌治疗的新靶点。
英文摘要:
      ABSTRACT Objective:To study the Cdk1 protein expression of ovarian cancer tissues and the relationship between Cdk1 level and the chemotherapy resistance and prognosis of ovarian cancer patients. Methods:The Cdk1 protein expression was assessed by immunehistochemistry (IHC) in 68 specimens of serous ovarian cancer. A correlation was analyzed between Cdk1 protein expression and clinical pathological features. The Kaplan-meier curve was used to analyse the correlation of Cdk1 expression with prognosis of ovarian cancer patients. Results:Cdk1 protein expression level was not related to age, lymph nodes metastasis, clinical stage and pathological differentiation(P>0.05), while high Cdk1 expression was associated with chemotherapy resistance(P = 0.040). And the chemo-resistance patients group had a much higher Cdk1 expression. Survival analysis found out that Cdk1 expression was an independent factor of PFS of ovarian cancer patients. Conclusion:Our data represent firstly that Cdk1 protein expression may contribute to chemotherapy resistance and prognosis of serous ovarian carcinoma. Cdk1 may be a promising therapy target for serous ovarian cancer.
View Full Text   View/Add Comment  Download reader
Close